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Oral Presentations 19activity regulated by Killer Immunoglobulin Receptor (KIR) genes
may tip the balance towards either detrimental or beneficial out-
comes. Both recipients and donors of 605 first allogeneic non-T de-
pleted transplants were retrospectively KIR genotyped. In the non-
HLA identical transplants, 92 inhibitory KIR ligand (iKIRL) mis-
matched cases displayed the worst five-year overall survival (OS,
20%) perhaps due to higher non-relapse mortality. In contrast,
75 transplants with only an HLA class-I antigen (Ag) incompatibil-
ity, but without an iKIRL incompatibility had significantly better
OS (41%, p\0.001), which was similar to that (39%) of the Class
I allele mismatched transplants, suggesting that incompatible
iKIRLs exacerbated the effect of HLA Class I mismatches. In the
HLA identical cases, the presence of both patient and donor
2DL/S2 resulted in a better OS (72% vs 58%, p\0.01) due to
less relapse. Interestingly, the impact was concentrated in HLA-
Cw iKIRL group 1 homozygotes. The absence of 2DL/S2 in the re-
cipients decreased OS by 20% (72% vs 52%, p\0.001). The effect
was not observed in the 10/10 (HLA-A, B, C, DRB1, DQB1)
matched transplant cases, suggesting that, NK cell activity in
HCT recipients, may be beneficial when the alloimmune response
is less stimulated. Our study reflects the diversified role of NK cells
inHCT, and suggests that KIR genotypingmay be useful in clinical
practice.IMMUNE RECONSTITUTION
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Viral infections cause morbidity and mortality in allogeneic
HSCT recipients. To treat the underlying problem, namely lack
of antigen-specific T cells, we and others have successfully gener-
ated and infused adoptive T-cell lines specific for EBV, CMV and
Adenovirus. We have shown that as few as 2  105/kg trivirus-
specific cytotoxic T lymphocytes (CTL) proliferated by several
logs post-infusion and appeared to protect the recipients against
all three viruses. Despite the encouraging clinical results, broader
implementation of the approach is limited by (i) the usage of infec-
tious virus material (EBV/Adv) and (ii) the prolonged culture (3
months for EBV-LCL production and CTL stimulation). Finally,
(iii) ‘‘antigenic competition’’ between multiple viral antigens
limits the extension to additional viruses. To overcome these
limitations we have developed an approach to rapidly produce
multivirus-specific CTL without using adenoviral vectors or
EBV-LCL. Using nucleofection we consistently detected GFP
transgene expression of 39% of transfected DCs, without ad-
versely affecting cell viability or DC maturation status. Coculture
of p-Shuttle-pp65-GFP-transfected DCs with PBMCs from
CMV seropositive individuals reactivated CMV-specific T-cells,
which were detectable 9 days after stimulation, at higher frequen-
cies (as measured by g-IFNELIspot and Pentamer analysis (HLA-
A2, NLV)) than lines generated using our standard protocol with
Ad5f35pp65-transduced DCs as APCs. Importantly, this protocol
could also be used to reactivate T cells against multiple viruses.
Using a panel of p-Shuttle plasmids encoding LMP2 and
BZLF1 (EBV), Large T (BK), and Hexon and Penton (Adv), we
amplified CTLs from seropositive donors specific for the different
viruses. Furthermore, we demonstrated that by pooling trans-
fected DCs prior to PBMC stimulation, we could reproducibly
generate multivirus-specific CTL lines, specific for all the stimu-
lating antigens, without observing antigenic competition. To
shorten the CTL production process, we established the selection
of highly virus-specific T cells by IFN-g capture 24 hours after
DC stimulation. In summary, we have established two GMP-ap-
plicable protocols for the rapid generation (\10 days) of CTL
without using infectious material. In 10 days we can generatemono- or multivirus -specific CTL lines for prophylactic applica-
tion. By performing IFN-g selection we can rapidly generate
virus-specific CTLs for treatment of acute infection.45
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The ability to accelerate immune reconstitution following
haplo-mismatched stem cell transplantion (SCT) would limit in-
fections and disease relapse, and provide a unique opportunity to
transplant the large number of patients who cannot find an HLA-
matched donor. We present results of a Phase I clinical trial of
haplo-mismatched allogeneic SCT supplemented with a donor
lymphocyte infusion (DLI) photodynamically depleted of host-re-
active T cells using dibromorhodamine as photosensitizer and
visible light illumination (512 nm) (ATIR-PDT, Kiadis Pharma).
Nineteen patients (11 M, 8 F) with high-risk hematologic malig-
nancies (mostly refractory or relapsed acute myeloid leukemia
(10) and myelodysplastic syndromes (4)) entered the trial. Median
age at SCT was 54 years (range: 19–62). Increasing doses of
PDT-treated donor cells (1  104 to 5.0  106 CD31 cells/kg)
were administered on day 34 6 6 after transplant. Greater than
95% of anti-host cytotoxic T lymphocyte precursors (CTLp)
were depleted from DLIs. All stem cell grafts underwent in vitro
immunomagnetic T cell depletion using CD341 positive cell se-
lection (Miltenyi). The myeloablative regimen consisted of TBI
(1200 cGy), thiotepa (5 mg/kg) and fludarabine (40 mg/m2/day
for 5 days) followed by infusion of CD3 depleted hematopoietic
stem cell grafts. No GVHD prophylaxis was administered. All pa-
tients showed complete donor chimerism and durable hemato-
logic engraftment. No patient developed acute GVHD (grade
II-IV). Eight patients died: 4 of relapsed leukemia (3 AML; 1
ALL) and 4 of infections, all after day1300. In the first 7 patients
who received 1.3  105 or less CD31 cells/kg, 11 infectious ep-
isodes (4 lethal) occurred in these 7 pts (100% of pts). In sharp
contrast, only 5 infectious episodes (none lethal) were observed
in 3 (27%) of the following 11 patients receiving DLI with the
highest doses of CD31 cells (3.2  105 to 5.0  106 CD31
cells/kg) (p \0.05). Chronic GVHD developed in 5 patients,
mostly in those receiving higher T cell doses, and responded rap-
idly to steroid-based immunesuppression. The overall survival is
67% at 2 years (median follow-up: 10.5 mo). Our results indicate
that the post-transplant infusion of an ATIR-PDT treated DLI is
feasible, does not induce acute GVHD, and suggests a clinical
benefit for patients receiving the highest DLI doses to accelerate
T cell reconstitution.46
RAPID RECOVERY OF ABSOLUTE LYMPHOCYTE COUNTS (ALC) IS PRE-
DICTIVE OF FAVORABLE OUTCOMES FOLLOWING UMBILICAL CORD
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After UCB transplantation, neutrophil recovery is markedly
slower than other stem cell sources. The kinetics of lymphocyte re-
covery and their significance has not been extensively evaluated.
We analyzed the maximumweekly ALC based on total white count
and automated differential. To assess the impact of ALC on
transplant outcomes, we analyzed 80 consecutive AML patients
transplanted with UCB after a myeloablative conditioning from
2001–6. Six patients with graft failure or early death were excluded,
resulting in 74 (92.5%) evaluable patients. The median age was
21.4 yrs (range 0.5–43.9). The majority of patients (85.1%) re-
ceived cyclophosphamide (60mg/kg x 2), fludarabine (75mg/m2)
